MedTrace Logo

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

NCT04896853 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-05-14

No results posted yet for this study

Summary

To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.

Conditions

  • COVID-19 Acute Respiratory Distress Syndrome
  • Influenza A
  • Metapneumovirus Pneumonia
  • Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL

ProTrans®

Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells

Sponsors & Collaborators

  • Karolinska Trial Alliance

    collaborator INDUSTRY

  • NextCell Pharma Ab

    lead INDUSTRY

Principal Investigators

  • Mathias Svahn, PhD · NextCell Pharma

  • Josefine Sundh, MD · Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-18
Primary Completion
2027-03-31
Completion
2027-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04896853 on ClinicalTrials.gov